BerGenBio ASA (BRRGF)
BerGenBio ASA operates in the Biotechnology industry of the Healthcare sector, headquartered in Bergen, NO. The stock last traded at $97.09, up 0.00% on the session, giving a market capitalisation of $9.49B. On trailing twelve-month figures it carries a trailing P/E of -1.00, a net margin of -877.4%. Its beta of 1.31 implies it has historically moved more than the broad market.
BerGenBio ASA is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapies for challenging conditions. This includes cancers that are immune-evasive, drug-resistant, or metastatic, as well as various respiratory diseases. Its leading drug candidate, Bemcentinib, is an orally available, small molecule AXL inhibitor that has progressed to Phase II clinical development. This involves studies across several significant cancer indications and for COVID-19. Specifically, its Phase II trials are focused on treating non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Another promising compound in its pipeline is tilvestamab, an anti-AXL antibody currently undergoing Phase Ib clinical evaluation. The company maintains a collaborative agreement with Merck & Co. concerning its clinical trial initiatives. Founded in 2007, BerGenBio ASA is headquartered in Bergen, Norway.
BerGenBio ASA is most often compared with the following Healthcare names: